Background: Subgroups of patients registered on a kidney transplant waiting list have higher than usual mortality levels. This study used data from the French Renal Epidemiology and Information Network (REIN) Registry to quantify the impact over time of various comorbidities on the excess risk of death among patients on the waiting list. Methods: Lexis diagrams were used to analyze time since onset of end-stage renal disease and time since registration on the waiting list. The number of excess deaths was calculated by comparison with the number of expected deaths in the general population of the same age and sex. Results: During 45,013 person-years of follow-up, 7,224 patients died, 5,956 (82%) more than expected relative to the general population. There were 101 deaths among wait-listed dialysis patients, 76 more than expected. The excess risk of death increased by 45% per additional year on the waiting list (18-79%, p = 0.0005). Time from end-stage renal disease onset until list registration (p = 0.004), time since registration (p < 0.001), age >65 years (p = 0.008), the presence of a primary renal disease (p = 0.028), and the number of comorbidities (p = 0.035) were independent predictors of death while on the waiting list. Conclusions: The excess risk of death while on the waiting list increased faster in patients with comorbidities. These results require consideration of ways to accelerate access to transplantation in high-risk patients.

Keywords:
Transplantation, Waiting list, Excess risk of death, Organ allocation, Kidney
1.
Renal Epidemiology and Information Network: 2010 Annual Report. Nephrol Ther 2012;8(supp 1):S1-S168.
2.
US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
3.
McDonald SP, Russ GR, Kerr PG, Collins JF, Australia and New Zealand Dialysis and Transplant Registry: ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis 2002;40:1122-1131.
4.
Kramer A, Stel V, Zoccali C, et al: An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrol Dial Transplant 2009;24:3557-3566.
5.
Wolfe RA, Ashby VB, Milford EL, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-1730.
6.
McDonald SP, Russ GR: Survival of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001. Nephrol Dial Transplant 2002;17:2212-2219.
7.
Rabbat CG, Thorpe KE, Russell JD, Churchill DN: Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000;11:917-922.
8.
Medin C, Elinder CG, Hylander B, Blom B, Wilczek H: Survival of patients who have been on a waiting list for renal transplantation. Nephrol Dial Transplant 2000;15:701-704.
9.
Johnson DW, Herzig K, Purdie D, et al: A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000;69:794-799.
10.
Villar E, Rabilloud M, Berthoux P, Vialtel P, Labeeuw M, Pouteil-Noble C: A multicentre study of registration on renal transplantation waiting list of the elderly and patients with type 2 diabetes. Nephrol Dial Transplant 2004;19:207-214.
11.
Bayat S, Frimat L, Thilly N, Loos C, Briançon S, Kessler M: Medical and non-medical determinants of access to renal transplant waiting list in a French community-based network of care. Nephrol Dial Transplant 2006;21:2900-2907.
12.
Oniscu GC, Schalkwijk AA, Johnson RJ, Brown H, Forsythe JL: Equity of access to renal transplant waiting list and renal transplantation in Scotland: cohort study. BMJ 2003;327:1261.
13.
Descamps C, Labeeuw M, Trolliet P, et al: Confounding factors for early death in end-stage renal disease patients: role of emergency dialysis start. Hemodial Int 2011;15:23-29.
14.
Karamé A, Labeeuw M, Trolliet P, et al: The impact of type 2 diabetes on mortality in end-stage renal disease patients differs between genders. Nephron Clin Pract 2009;112:c268-c275.
15.
Snyder JJ, Kasiske BL, Maclean R: Peripheral arterial disease and renal transplantation. J Am Soc Nephrol 2006;17:2056-2068.
16.
Villar E, Remontet L, Labeeuw M, Ecochard R: Effect of age, sex and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol 2007;18:2125-2134.
17.
Couchoud C, Stengel B, Landais P, et al: The Renal Epidemiology and Information Network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant 2006;21:411-418.
18.
Breslow NE, Day NE: Statistical Methods in Cancer Research. Vol. II: The Design and Analysis of Cohort Studies. Lyon, International Agency for Research on Cancer Press, 1987, pp 1-406.
19.
Hakulinen T, Tenkanen L: Regression analysis of relative survival rates. Appl Stat 1987;36:309-317.
20.
McCullagh P, Nelder JA: Generalized Linear Models, ed 2. Boca Raton, Chapman & Hall/CRC, 1989, pp 40-43.
21.
Couchoud C, Lassalle M, Stengel B, Jacquelinet C: Rapport annuel 2009. Réseau Epidémiologie et Information en Néphrologie. http://www.agence-biomedecine.fr/uploads/document/Rapport-REIN-2009-Web%20sept2011.pdf (accessed November 25, 2011).
22.
Jacquelinet C, Audry B, Golbreich C, et al: Changing Kidney Allocation Policy in France: The Value of Simulation. AMIA Annu Symp Proc, 2006, pp 374-378.
23.
Schold JD, Meier-Kriesche HU: Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006;1:532-538.
24.
Courtney AE, Maxwell AP: The challenge of doing what is right in renal transplantation: balancing equity and utility. Nephron Clin Pract 2009;111:c62-c68.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.